
NEWS RELEASE

iX Biopharma Secures U.S. Partner to Accelerate Commercialisation of WaferiX® Portfolio

- ✓ Strategic U.S. partnership marks key milestone in iX Biopharma's transformation from R&D to commercialisation
- ✓ Capital-light joint venture to unlock immediate market access for WaferiX® portfolio through Orion's FDA-licensed compounding network

SINGAPORE, 6 November 2025 — iX Biopharma Ltd (SGX: 42C) ("**iX Biopharma**" or "**the Company**") has taken a major step toward commercialising its breakthrough WaferiX® technology and products, signing a non-binding term sheet with FDA-licensed Orion Specialty Labs ("**Orion**") to establish a manufacturing and commercialisation base in the United States ("**U.S.**").

This partnership marks a transformational milestone in iX's evolution from a research-focused innovation company into a commercial-stage enterprise with direct access to the world's largest healthcare market.

Capital-Light Expansion

iX Biopharma will retain strategic control with a 75% stake in the future joint venture, while Orion will hold 25%. The partnership model is capital-light for iX Biopharma, with Orion funding new manufacturing equipment and working capital.

By partnering Orion and tapping into its 503B and 503A compounding networks serving hospitals, clinics, and telehealth channels across the U.S., iX Biopharma will benefit from speed to market and have a clear pathway to monetise its WaferiX® portfolio, without the need for additional further clinical trials, conserving time and resources.

"With Orion's operational base, we will rapidly bring market-leading, differentiated products to patients in the United States to address high-demand treatment areas," said **Eva Tan, Chief Commercial Officer of iX Biopharma**. "By meeting the growing demand for needle-free, fast-acting therapies, we are well placed to capture significant market share and build lasting leadership in the personalised medicine space."

The U.S. compounding market, worth US\$6.3 billion in 2024, is projected to exceed US\$10 billion by 2033¹, driven by telehealth and personalised medicine.

¹ <https://www.biospace.com/press-releases/u-s-compounding-pharmacies-market-size-to-hit-usd-10-76-billion-by-2033>

From Innovation to Access

At the core of iX Biopharma's innovation are its patented sublingual drug delivery technology platforms that enables medicines to dissolve quickly under the tongue for greater bioavailability, faster onset, and more predictable dosing.

The platforms enable drug repurposing, transforming injectable or poorly absorbed oral medications into effective sublingual treatments that expand access and unlock new therapeutic opportunities. This approach opens access to therapies across key categories such as pain management, hormone therapy, weight management, and longevity medicine, and underpins iX's portfolio of 22 pharmaceutical and 7 nutraceutical products.

About iX Biopharma Ltd

iX Biopharma (SGX: 42C) is a specialty pharmaceutical company with expertise in novel drug delivery systems and drug repurposing. Its patented WaferiX® platform enables rapid, effective sublingual dosing for pharmaceuticals and nutraceuticals.

About Orion Specialty Labs

Orion is an FDA-licensed 503B compounding pharmacy based in Nevada, U.S., wholly owned by GLD Partners, LP, a life sciences investment firm headquartered in Los Angeles.

Note: This media release is to be read in conjunction with the announcement issued on SGXNet on the same date.

Contact for media:

Eva Tan
Chief Commercial Officer
T: +65 6235 3212
E: eva.tan@ixbiopharma.com

Daniel Chow
Director of Business Development
T: +65 6235 2270
E: daniel.chow@ixbiopharma.com